We are live on
!
Find out more
Zurich Cantonal Bank Portfolio holdings
AUM
$46B
1-Year Est. Return
27.59%
This Fund
S&P 500
This Quarter
Est. Return
-1.84%
1 Year Est. Return
+27.59%
3 Year Est. Return
+97.89%
5 Year Est. Return
+132.69%
10 Year Est. Return
+500.34%
AUM
$46B
AUM Growth
-$375M
(-0.81%)
Cap. Flow
+$1.95B
Cap. Flow
% of AUM
4.25%
Top 10 Holdings %
Top 10 Hldgs %
33.14%
Holding
3,504
New
954
Increased
1,038
Reduced
277
Closed
939
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UBS Group
UBS
|
+$2.43B |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$1.33B |
| 3 |
Amazon
AMZN
|
+$1.29B |
| 4 |
Meta Platforms (Facebook)
META
|
+$872M |
| 5 |
Eli Lilly
LLY
|
+$647M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bank of America
BAC
|
+$75.4M |
| 2 |
Tesla
TSLA
|
+$64.6M |
| 3 |
MRSH
Marsh
MRSH
|
+$38.2M |
| 4 |
Logitech
LOGI
|
+$37M |
| 5 |
Xylem
XYL
|
+$36.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.12% |
| 2 | Financials | 15.91% |
| 3 | Healthcare | 11.42% |
| 4 | Industrials | 8.98% |
| 5 | Consumer Discretionary | 8.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2401
Kodiak Sciences
KOD
$2.73B
| $20.5K | ﹤0.01% |
+539
| New | +$13.9K |
|
2402
Regenxbio
RGNX
$672M
| $20K | ﹤0.01% |
2,390
+1,020
| +74% | +$10.7K |
|
2403
Frontier Group Holdings
ULCC
$1.83B
| $19.6K | ﹤0.01% |
5,566
| – | – |
|
|
BIOA
2404
BioAge Labs
BIOA
$488M
| $18.9K | ﹤0.01% |
+1,082
| New | +$20.8K |
|
2405
Aclaris Therapeutics
ACRS
$888M
| $18.8K | ﹤0.01% |
+5,006
| New | +$16.9K |
|
2406
SOPHiA GENETICS
SOPH
$529M
| $18.6K | ﹤0.01% |
3,755
| – | – |
|
2407
Entrada Therapeutics
TRDA
$274M
| $17.9K | ﹤0.01% |
1,417
+985
| +228% | +$11.3K |
|
|
JKS
2408
JinkoSolar
JKS
$826M
| $17.4K | ﹤0.01% |
+683
| New | +$18K |
|
2409
Design Therapeutics
DSGN
$849M
| $17K | ﹤0.01% |
1,594
+367
| +30% | +$3.71K |
|
|
RAPP
2410
Rapport Therapeutics
RAPP
$2.03B
| $16.1K | ﹤0.01% |
+513
| New | +$14.4K |
|
2411
GlobalFoundries
GFS
$27.1B
| $15.9K | ﹤0.01% |
358
| – | – |
|
|
DQ
2412
Daqo New Energy
DQ
$899M
| $15.5K | ﹤0.01% |
731
| – | – |
|
|
SION
2413
Sionna Therapeutics
SION
$2.14B
| $14.9K | ﹤0.01% |
+371
| New | +$14.2K |
|
2414
Kyverna Therapeutics
KYTX
$464M
| $14.1K | ﹤0.01% |
+1,629
| New | +$13.6K |
|
|
MBX
2415
MBX Biosciences
MBX
$3.21B
| $14K | ﹤0.01% |
+470
| New | +$16K |
|
2416
Inhibrx
INBX
$1.23B
| $13K | ﹤0.01% |
194
-304
| -61% | -$22.6K |
|
2417
Rocket Pharmaceuticals
RCKT
$382M
| $12.7K | ﹤0.01% |
3,557
| – | – |
|
|
SEPN
2418
Septerna Inc
SEPN
$1.75B
| $12.2K | ﹤0.01% |
+508
| New | +$13.4K |
|
2419
Replimune Group
REPL
$994M
| $12.1K | ﹤0.01% |
+1,586
| New | +$12.1K |
|
|
CMPS
2420
Compass Pathways
CMPS
$1.83B
| $12.1K | ﹤0.01% |
+2,192
| New | +$14.7K |
|
2421
Pacific Biosciences
PACB
$404M
| $12.1K | ﹤0.01% |
+9,146
| New | +$16.4K |
|
2422
Vanda Pharmaceuticals
VNDA
$306M
| $12K | ﹤0.01% |
+1,743
| New | +$13.4K |
|
|
ABVX
2423
Abivax
ABVX
$10.9B
| $11.7K | ﹤0.01% |
+105
| New | +$12.4K |
|
2424
Enanta Pharmaceuticals
ENTA
$384M
| $11.4K | ﹤0.01% |
+906
| New | +$12.1K |
|
2425
Zegna
ZGN
$4.08B
| $10.9K | ﹤0.01% |
1,049
+117
| +13% | +$1.21K |
|
Similar funds
LP
TI
Zurich Cantonal Bank's Q1 2026 Portfolio in Review
As of Q1 2026, Zurich Cantonal Bank held 3,504 positions worth $46B, down 0.81% from $46.3B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Zurich Cantonal Bank deployed $1.95B of net new capital in Q1 2026, opening 954 new positions and adding to 1,038 existing holdings. Its largest new stake was UBS Group: 56,674,567 shares worth $2.17B.
By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Bank of America, an estimated $75.4M trimmed.
- Zurich Cantonal Bank's largest Q1 2026 buy was UBS Group: 56,674,567 shares worth $2.17B.
- Zurich Cantonal Bank added most to Microsoft in Q1 2026, an estimated $221M increase.
- Zurich Cantonal Bank's biggest Q1 2026 reduction was Bank of America, cutting an estimated $75.4M.
- Zurich Cantonal Bank fully exited CyberArk in Q1 2026, selling an estimated $12.7M.
- Zurich Cantonal Bank's ten largest holdings make up 33% of its $46B portfolio in Q1 2026.
- Zurich Cantonal Bank opened 954 new positions and closed 939 in Q1 2026.
- Zurich Cantonal Bank's portfolio value fell 0.81% quarter-over-quarter to $46B.
Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.